Biohaven Ltd. is hoping it will have better luck this time around as it prepares to apply for US Food and Drug Administration approval of troriluzole in spinocerebellar ataxia (SCA) based on a real-world evidence (RWE) trial after the drug failed in prior studies, resulting in a refuse-to-file (RTF) letter from the agency. However, some analysts have pointed to continued skepticism about its chances despite the company having designed the study in discussion with the FDA.
Biohaven Returns With Positive RWE Data In Spinocerebellar Ataxia
The company announced data from a real-world evidence study that compared a three-year analysis of existing Phase III data with an external control and plans to file with the FDA in the fourth quarter.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.